Online citations, reference lists, and bibliographies.
← Back to Search

The Effects Of An Intentional Transition From Extrapleural Pneumonectomy To Extended Pleurectomy/decortication.

A. Sharkey, S. Tenconi, A. Nakas, D. Waller
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES For many years, extrapleural pneumonectomy (EPP) was the operation of choice for the radical management of pleural mesothelioma in the UK. However, doubts surrounding the efficacy of EPP, and the change in demographics of the affected population, have prompted a transition in our practice towards extended pleurectomy/decortication (EPD). The aim of this study was to determine the effects an intentional transition from EPP to EPD has had on patient outcome. METHODS Data from 362 patients undergoing radical surgery (229 EPD, 133 EPP) during 1999-2014 were included. Demographics and outcome were compared between the two groups; EPP versus EPD. RESULTS The median age of patients undergoing EPD was significantly higher than those undergoing EPP [57 years (range 14-70 years) vs 65 years (range 42-81 years), P < 0.001]. There was a significantly higher proportion of patients with performance status ≥1 in the EPD group (46.3 vs 35.4%, P = 0.047). There was no difference in the median length of hospital stay between the two groups [14 days (range 1-133 days) vs 13 days (range 0-93 days), P = 0.409]. There was also no difference between the groups in terms of in-hospital mortality (EPP 5.3% and EPD 6.6%, P = 0.389), 30-day mortality [EPP 8 (6.0%) and EPD 8 (3.5%), P = 0.294] or 90-day mortality [EPP 18 (13.5%) and EPD 21 (9.2%), P = 0.220]. There was a significantly higher early reoperation rate in the EPP group (15.0 vs 6.2%, P = 0.008) but a significantly higher late reoperation rate in the EPD group (0.8 vs 5.3%, P = 0.037). There was no significant difference in overall survival or disease-free interval between the two groups (P = 0.899 and P = 0.399, respectively). However, overall survival was significantly greater in patients over the age of 65 undergoing EPD (12.5 vs 4.7 months, P = 0.001). CONCLUSION The transition from EPP to EPD in our standard practice has enabled us to operate on more elderly, frail patients with no significant increase in use of hospital resources, and without detriment to overall survival.
This paper references
10.1093/ejcts/ezt664
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
A. Nakas (2014)
10.1038/bjc.1982.15
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment.
J. Peto (1982)
10.1093/ejcts/ezr192
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
MESOVATS: a multi-centre randomised controlled trial of video assisted thoracoscopic pleurectomy versus talc pleurodesis in malignant pleura mesothelioma
RC Rintoul (2013)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1016/j.lungcan.2013.04.024
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
C. Cao (2013)
10.1016/j.athoracsur.2009.12.041
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
B. Balduyck (2010)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1016/j.lungcan.2013.04.019
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
S. Boeluekbas (2013)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)



This paper is referenced by
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1080/17476348.2020.1688147
Extrapleural pneumonectomies for pleural mesothelioma
Eleonora Faccioli (2019)
10.21037/shc.2018.06.06
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
10.21037/jtd.2018.01.171
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
10.1053/j.semtcvs.2019.01.010
Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
S. Hasegawa (2019)
10.1245/s10434-019-07351-6
Management of Malignant Pleural Mesothelioma in the Elderly Population
V. Verma (2019)
10.1093/icvts/ivw422
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.
Arthur Kostron (2017)
10.1093/annonc/mdy195
Pleural mesothelioma: is the surgeon still there?
I. Opitz (2018)
10.1097/MCP.0000000000000389
Surgery as part of radical treatment for malignant pleural mesothelioma
D. Waller (2017)
10.1245/s10434-020-09275-y
Complications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Akifumi Nakamura (2020)
10.21037/atm.2017.03.82
Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).
H. Batırel (2017)
10.1007/s11748-018-1027-6
Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma
D. Magouliotis (2018)
10.1007/s00268-017-4264-4
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
W. Vigneswaran (2017)
10.5603/ARM.2019.0051
Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.
M. Sayan (2019)
10.3322/caac.21498
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
D. Mahvi (2018)
10.1016/J.LUNGCAN.2019.03.026
Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.
I. Berger (2019)
10.21037/jovs.2017.05.05
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
P. Perikleous (2017)
10.26663/cts.2019.00123
Sustained preservation of pulmonary function after pleurectomy/ decortication: should it be the main reason to perform surgery in malignant pleural mesothelioma patients?
S. Ozer (2019)
10.21037/SHC.2017.06.02
Pleurectomy/decortication for malignant pleural mesothelioma
Mariano Di Martino (2017)
10.21037/tlcr.2018.06.07
Extended pleurectomy decortication: the current role.
R. Bilancia (2018)
10.1093/icvts/ivx221
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.
A. Sharkey (2017)
10.1016/j.jtcvs.2017.12.131
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
H. Batırel (2018)
10.21037/jtd.2017.10.16
Surgery for malignant pleural mesothelioma: an international guidelines review.
S. Ricciardi (2018)
10.3390/jcm9072153
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
Y. Ichiki (2020)
10.1586/17476348.2016.1171147
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence
P. Bertoglio (2016)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.21037/atm.2017.03.88
A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2017)
10.1007/978-3-319-96244-3_1
History of Pleural Surgical Treatment
Dharmaraj Chauhan (2019)
10.1016/j.jtho.2018.08.001
Surgery in Malignant Pleural Mesothelioma
R. Bueno (2018)
Semantic Scholar Logo Some data provided by SemanticScholar